Melanoma Clinical Trials in Nashville

Showing 161-180 of 322 trials

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.

Choroidal MelanomaIndeterminate Lesions of Eye

Aura Biosciences500 participantsStarted Mar 2019

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +13 more locations

COMPLETED< 1 mile

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

NCT03267381

To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of treatment responses, or predict risk of relapse, in conjunction with standard clinical assessment and imaging.

Melanoma

Vanderbilt-Ingram Cancer Center37 participantsStarted Oct 2017

Nashville, Tennessee, United States

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

Melanoma Trials in Other Cities

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Safety Study of SEA-CD40 in Cancer Patients

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Study of ASN003 in Subjects With Advanced Solid Tumors

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Nashville